The effect of kangxianling (KXL) on hepatic fibrosis resulting from schistosomiasis was investigated in mice. Murine models with hepatic fibrosis of schistosomiasis japonicum were established and killed after being tr...The effect of kangxianling (KXL) on hepatic fibrosis resulting from schistosomiasis was investigated in mice. Murine models with hepatic fibrosis of schistosomiasis japonicum were established and killed after being treated with KXL for 40 d. The experimental results showed that in the KXL group the liver weight (0. 53±0. 07 g/10g ·bw ), the hepatic fibrosis degree (0. 71±0. 19 marks),and the content of collagen ( 14. 44 ±4. 41 mg/g powder) and type III procollagen (27. 83±5. 82 ug/L) in the livers were significantly different from those of the control group (P <0 .05 or P<0.01 ). Through pathological examination,it was found that KXL could significantly soften cirrhotic liver, ameliorate hepatic swelling, and inhibit the deposition of collagen protein and proliferation of collagen fibers in the liver. These findings were analyzed for their relationship with the inhibiton of collagen synthesis, improvement of collagen degradation ,promotion of hepatic circulation and nutrition and reduction of damage to hepatocytes. The study suggested that KXL is a new effective and prospective drug for therapy of schistosomal hepatic fibrosis.展开更多
文摘The effect of kangxianling (KXL) on hepatic fibrosis resulting from schistosomiasis was investigated in mice. Murine models with hepatic fibrosis of schistosomiasis japonicum were established and killed after being treated with KXL for 40 d. The experimental results showed that in the KXL group the liver weight (0. 53±0. 07 g/10g ·bw ), the hepatic fibrosis degree (0. 71±0. 19 marks),and the content of collagen ( 14. 44 ±4. 41 mg/g powder) and type III procollagen (27. 83±5. 82 ug/L) in the livers were significantly different from those of the control group (P <0 .05 or P<0.01 ). Through pathological examination,it was found that KXL could significantly soften cirrhotic liver, ameliorate hepatic swelling, and inhibit the deposition of collagen protein and proliferation of collagen fibers in the liver. These findings were analyzed for their relationship with the inhibiton of collagen synthesis, improvement of collagen degradation ,promotion of hepatic circulation and nutrition and reduction of damage to hepatocytes. The study suggested that KXL is a new effective and prospective drug for therapy of schistosomal hepatic fibrosis.
